HLS Therapeutics Inc.

HLS

CA40390B1094

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 10:09:22 2024-04-18 am EDT			5-day change	1st Jan Change
4.9 ^CAD	+0.20%		-2.20%	+24.05%

Apr. 08	HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA	CI
Mar. 14	Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024

Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 4, 2021.

May 05, 2022 at 06:57 am EDT

From January 1, 2022 to March 31, 2022, the company has repurchased 1,800 shares, representing 0.005547% for CAD 0.03 million. With this, the company has completed the repurchase of 1,800 shares, representing 0.005547% for CAD 0.03 million under the buyback announced on November 4, 2021.

Latest news about HLS Therapeutics Inc.

HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA	Apr. 08	CI
Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update	Mar. 14	MT
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022	Mar. 14	MT
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million	Mar. 14	MT
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024	Mar. 14	CI
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan	Feb. 06	MT
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	Feb. 06	MT
HLS Therapeutics Inc. Announces CFO Changes	Dec. 18	CI
HLS Therapeutics Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	Dec. 18	MT
HLS Therapeutics Brief: Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	Dec. 18	MT
HLS Therapeutics Brief: Adds Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo	Nov. 14	MT
HLS Therapeutics Brief: Says New REDUCE-IT Analyses Show Vascepa (Icosapent Ethyl) Associated with 29% Relative Risk Reduction Vs Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline	Nov. 14	MT
HLS Therapeutics Inc. Announces Results from New REDUCE-IT Analyses	Nov. 14	CI
HLS Therapeutics Inc.'s Equity Buyback announced on November 10, 2022, has expired.	Nov. 12	CI
HLS Therapeutics Downgraded to Hold at Stifel GMP on Revenue Concerns; Price Target Cut to C$5.00	Nov. 10	MT
HLS Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022.	Nov. 09	CI
HLS Therapeutics Inc. announces an Equity Buyback for 1,607,892 shares, representing 5% of its issued share capital.	Nov. 09	CI
Transcript : HLS Therapeutics Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
HLS Therapeutics Reports Q3 2023 Revenue of US$16.0 Million, Renews Normal Course Issuer Bid	Nov. 09	MT
HLS Therapeutics Brief: Q3 2023 revenue was US$16.0 million, Adjusted EBITDA was $5.1 million and cash from operations was $5.4 million; Renewing Normal Course Issuer Bid	Nov. 09	MT
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ

Chart HLS Therapeutics Inc.

Duration

Period

More charts

Company Profile

HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for HLS Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.538 USD

Average target price

4.5 USD

Spread / Average Target

+27.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
HLS THERAPEUTICS INC.	+24.05%	113M
MCKESSON CORPORATION	+12.19%	69.11B
CARDINAL HEALTH, INC.	+5.53%	25.91B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+5.02%	8.01B
SINOPHARM GROUP CO. LTD.	-3.28%	7.91B
HUADONG MEDICINE CO., LTD	-27.52%	7.27B
H. LUNDBECK A/S	-0.67%	4.51B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+21.54%	4.48B
EBOS GROUP LIMITED	-2.45%	3.95B
GALENICA AG	-3.99%	3.79B

Pharmaceuticals Wholesale

HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Pharmaceuticals

Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 4, 2021.

EPS Revisions